CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Shares of Alumis ALMS surged 95.3% on Jan. 6, after the company announced positive top-line data from its two phase III ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Pediatric patients with plaque psoriasis receiving apremilast vs placebo experienced significantly greater improvements in global disease activity and skin involvement. Treatment with apremilast was ...

Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 ...

Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET –SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...

ATLANTA, Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX® ...

Shares of Alumis surged after the company said both of its phase three trials of its envudeucitinib drug for moderate-to-severe plaque psoriasis met all primary and secondary endpoints. The stock more ...